Chimeric antigen receptor and car-t cells that bind cxcr5

A chimeric antigen receptor and antigen technology, which is applied in the field of reviewing various CAR technologies, can solve the problems of no CAR components and no mention of medical uses.

Pending Publication Date: 2020-05-01
MAX DELBRUCK CENT FUR MOLEKULARE MEDIZIN MDC
View PDF37 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

CD185 (CXCR5) is mentioned but no details on CAR components, medical use or target relevance at all

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chimeric antigen receptor and car-t cells that bind cxcr5
  • Chimeric antigen receptor and car-t cells that bind cxcr5
  • Chimeric antigen receptor and car-t cells that bind cxcr5

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0182] Chimeric Antigen Receptors:

[0183] According to the present invention, a chimeric antigen receptor polypeptide (CAR) comprises an extracellular antigen binding domain comprising an antibody or antibody fragment that binds a target antigen, a transmembrane domain and an intracellular domain. A CAR is generally described as comprising an extracellular domain (antigen-binding domain) derived from an antibody and an intracellular domain comprising a signaling component derived from a T cell signaling protein.

[0184] In a preferred embodiment, the extracellular domain preferably comprises variable regions from the heavy and light chains of immunoglobulins configured as single chain variable fragments (scFv). The scFv is preferably linked to a hinge region that provides flexibility and transduces signals by anchoring the transmembrane portion to the intracellular signaling domain. The transmembrane domain is preferably derived from CD8α or CD28. In first-generation CA...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen-binding domain, comprising an antibody or antibody fragment that binds a human CXC chemokine receptor type 5 (CXCR5) protein. The invention further relates to a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably aT cell, expressing the CAR of the invention and the use of said cell in the treatment of a medical disorder associated with the presence of pathogenic cells expressing CXCR5, preferably pathogenic mature B cells and / or memory B cells, and / or pathogenic T cells and / or T follicular helper cells, in particular mature B cell non-Hodgkin's lymphoma (B-NHL), T cell non-Hodgkin's lymphoma, or autoantibody-dependent autoimmune disease, preferably selected from systemic lupus erythematosus (SLE) or rheumatoid arthritis.

Description

[0001] describe [0002] The present invention relates to an isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen binding domain comprising a protein that binds to CXC chemokine receptor type 5 (CXC chemokine receptor type 5, CXCR5) antibodies or antibody fragments. The invention further relates to nucleic acid molecules encoding the CAR of the invention, genetically modified immune cells, preferably T cells, expressing the CAR of the invention, and the use of said cells in the treatment of medical conditions associated with the presence of pathogenic cells expressing CXCR5 The use of pathogenic cells expressing CXCR5 is preferably pathogenic mature B cells and / or memory B cells and / or pathogenic T cells and / or follicular helper T cells, especially mature B cells that are not Hodgkin's lymphoma (B-NHL), T-cell non-Hodgkin's lymphoma, or an autoantibody-dependent autoimmune disease, preferably selected from systemic lupus eryth...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/28C07K14/00A61K39/00
CPCC07K16/2866A61K2039/507C07K2317/622C07K2317/73C07K2319/03C07K2319/33C07K2319/70C07K14/7051C07K14/70517C07K14/70521C07K14/70578A61K2239/38A61K39/464421A61K39/4611C12N5/0636C12N5/0646A61K39/464412A61K2239/31A61K2239/48A61K39/4631A61P35/00A61K35/17C07K2317/24C07K2317/565C07K2319/02C12N2510/00
Inventor 乌塔·霍普肯阿明·雷姆尤利娅·布卢姆沃尔夫冈·乌克特
Owner MAX DELBRUCK CENT FUR MOLEKULARE MEDIZIN MDC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap